LUCID DIAGNOSTICS INC

Lucid Diagnostics stock soars 25.3% amid a 24‑hour rally, reaching $0.41 per share. Learn how the biotech firm’s esophageal diagnostics and market context could impact investors.

Lucid Diagnostics secures Medicare reimbursement for EsoGuard® and raises $15 M Series C convertible preferred stock, boosting cash flow and commercialization momentum.

Lucid Diagnostics drops sharply, falling 5.4% to $0.33 as investors doubt its esophageal‑diagnostic platform. Read why the market’s confidence has eroded and what could revive the stock.

Lucid Diagnostics drops 21% as investors weigh product, regulatory risks amid a 70M market cap—see what’s driving this volatile medical‑tech stock.